Novo Nordisk A/S
- NVO
- NYSE
- Drug manufacturers
- Diabetes/Obesity Therapeutics
- GLP-1 Drugs
$38.83
Today −0.99%Quote Oct 16, 2026, 08:00 PM UTC
−10.09%over the last month
Max drawdown −13.7%From 1-month high −10.2%3 months −21.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$171.36B
Quote Oct 16
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$42.33
+9.0% from here
Floor
$37.80
2.7% below price
Where the price sits
39 analysts
Analyst range, low to high
$40.00$47.00
- Price $38.83
- Resistance $39.26
- Consensus $42.33
The price is right under resistance. Analysts' average target sits about 9% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NVOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Drug manufacturers
Employees
68,794
Founded
1923